Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25908217 | 0.83 | CHRM2 (0.33) | CHRM3F2CHRM2CHRM1 | |
| SCHEMBL25907323 | 0.81 | CHRM3 (0.39) | CHRM3CHRM2CHRM1 | |
| SCHEMBL20476343 | 0.78 | CHRM3 (0.55) | CHRM3CHRM2CHRM1 | |
| SCHEMBL26529380 | 0.75 | CHRM3 (0.47) | CHRM3CHRM2CHRM1 | |
| SCHEMBL25907152 | 0.75 | GPR119 (0.45) | CHRM3KLKB1 | |
| SCHEMBL25907223 | 0.75 | CHRM3 (0.47) | CHRM3CHRM2CHRM1 | |
| Acetic Acid SCHEMBL20476349 | 0.74 | CHRM3 (0.54) | CHRM3CHRM2CHRM1 | |
| SCHEMBL25907319 | 0.74 | CHRM3 (0.33) | CHRM3CHRM2 | |
| SCHEMBL25908838 | 0.74 | CHRM3 (0.51) | CHRM3CHRM2CHRM1 | |
| SCHEMBL25908761 | 0.74 | CHRM3 (0.47) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4219485-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CYP3A43, ABCB1, ABCB11 | CHRM3 354/4885HDAC2 572/4885F2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.